 |
|
|
|
PROCYTE EXPANDS DIRECT TO CONSUMER LICENSE
Featuring NuGlow® Skin Care Products
Redmond, Wash.—May 19, 2004—ProCyte Corporation (OTCBB: PRCY.OB),
a company that develops and markets skin
care and procedure related products for the dermatology, cosmetic
surgery and spa markets based on its patented GHK Copper Peptide Complex®
technologies, today announced its licensee in the direct-mail infomercial market will
begin a major expansion of its innovative marketing programs. Steve
Dworman, a leader in the direct response industry and President of It
Really Works, LLC, has teamed with Steve Sheiner to launch their NuGlow®
skin care campaign to consumers
nationwide. Mr. Sheiner, a cofounder of MP-3, which was later sold to
Vivendi, has made a major investment in the privately-held company.
The NuGlow®
promotion features actress Nicolette Sheridan endorsing skin care
products using ProCyte’s GHK Copper Peptide technology. Market tests in
2003 proved extremely successful after testing the campaign for a year
period of time. The roll-out will begin late summer and early fall and
involve the mailing of 4–6 million direct response pieces to targeted
households with a history of purchasing from mail order offers.
“We are extremely
excited with the marketing focus Steve Dworman has created in his
direct-to-consumer skin care program,” said Jack Clifford, President.
“The potential revenue for ProCyte could be significant as the program
rolls-out and if product usage builds as planned. The early results are
very positive and consumer loyalty to the products is far better than
results seen in many direct response programs.”
ProCyte Corporation develops and markets products based on its patented,
clinically proven Copper Peptide technology for skin health, hair care
and wound care. The Company sells directly to dermatologists, plastic
and cosmetic surgeons, spas and salons and through licenses with
strategic partners into the consumer market, including its long-term
worldwide license agreement with Neutrogena®, a Johnson &
Johnson company. ProCyte brands include Neova®,
VitalCopper™,
Simple Solutions®
and AquaSanté®
Skin Care products; Complex Cu3®
Post-Procedure Skin Care; GraftCyte®
Hair Transplant Care; and Tricomin®
Advanced Care for Thinning Hair. The Company also has the exclusive
distribution rights for Cutanix Corporation’s Quadrinone®
technology in the U.S., Canada and Puerto Rico. Additional information
is available by visiting the Company’s website at www.procyte.com.
###
This release may contain forward-looking statements relating to the
research, development, commercialization, production, marketing and
distribution of the Company's products and future operating results,
which are subject to certain risks and uncertainties that could cause
actual results to differ materially from those projected.
The
words “believe,” “expect,” “intend,” “anticipate,” variations of such
words, and similar expressions
identify forward-looking statements, but their absence does not mean
that the statement is not forward-looking. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Factors
that could affect the Company’s actual results include its ability to
develop, commercialize and produce new products; the market acceptance
of existing and potential future products; the availability, cost and
timely delivery of materials and services from and performance of
third-party suppliers, manufacturers, distributors, licensees and other
collaborative partners; the satisfaction of regulatory requirements, and
the receipt, timing, terms and conditions of required regulatory
approvals. Reference is made to the Company’s Annual Report on Form
10-K for the year ended December 31, 2003 and its latest Quarterly
Report on Form 10‑Q filed with the Securities and Exchange Commission
for a more detailed description of such factors. Readers are cautioned
not to place undue reliance on these forward-looking statements, which
speak only as of the date of this release. The Company undertakes no
obligation to publicly update any forward-looking statement to reflect
new information, events or circumstances after the date of this release
or to reflect the occurrence of unanticipated events.
|
|
|
|
